Rituximab in Combination with Corticosteroids for the Treatment of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: A NICE Single Technology Appraisal

As part of its single technology appraisal (STA) process, the National Institute for Health and Care Excellence (NICE) invited the manufacturer of rituximab (Roche Products) to submit evidence of the clinical and cost effectiveness of rituximab in combination with corticosteroids for treatment of an...

Descripción completa

Detalles Bibliográficos
Autores principales: Latimer, Nicholas R., Carroll, Christopher, Wong, Ruth, Tappenden, Paul, Venning, Michael C., Luqmani, Raashid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2014
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4244572/
https://www.ncbi.nlm.nih.gov/pubmed/25059204
http://dx.doi.org/10.1007/s40273-014-0189-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4244572/
https://www.ncbi.nlm.nih.gov/pubmed/25059204
http://dx.doi.org/10.1007/s40273-014-0189-z

Ejemplares similares